Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages-Reference-Cited by-同舟云学术

Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages

Published:2017-11-23 Issue:8 Volume:33 Page:1362-1372
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:

Author:

Krämer Johannes¹²,Lenders Malte³,Canaan-Kühl Sima⁴,Nordbeck Peter¹,Üçeyler Nurcan¹⁵,Blaschke Daniela⁶,Duning Thomas⁷,Reiermann Stefanie³,Stypmann Jörg⁸,Brand Stefan-Martin⁹,Gottschling Timo¹⁰,Störk Stefan¹,Wanner Christoph¹,Sommer Claudia¹⁵,Brand Eva³,Weidemann Frank¹¹⁰

Affiliation:

1. Department of Internal Medicine I, Divisions of Cardiology and Nephrology, Comprehensive Heart Failure Center, Fabry Center for Interdisciplinary Therapy (FAZIT), University Hospital and University of Würzburg, Würzburg, Germany

2. Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany

3. Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, Interdisciplinary Fabry Center Münster, University Hospital Münster, Münster, Germany

4. Department of Medicine, Division of Nephrology, Charité, Campus Virchow-Klinikum, Berlin, Germany

5. Department of Neurology, University of Würzburg, Würzburg, Germany

6. Department of Medicine, Division of Cardiology, Charité, Campus Virchow-Klinikum, Berlin, Germany

7. Department of Neurology, University Hospital Münster, Münster, Germany

8. Department of Cardiovascular Medicine, Division of Cardiology, University Hospital Münster, Münster, Germany

9. Institute of Sports Medicine, Molecular Genetics of Cardiovascular Disease, University Hospital Münster, Münster, Germany

10. Katharinen-Hospital Unna, Unna, Germany

Funder

Genzyme Europe

Deutsche Forschungsgemeinschaft

Bundesministerium für Bildung und Forschung

BMBF

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/article-pdf/33/8/1362/25198429/gfx319.pdf

Reference38 articles.

1. Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease;Eng;N Engl J Med,2001

2. Enzyme replacement therapy in Fabry disease: a randomized controlled trial;Schiffmann;J Am Med Assoc,2001

3. Expert opinion on temporarytreatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT);Linthorst;Mol Genet Metab,2011

4. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients;Smid;Orphanet J Rare Dis,2011

5. Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease;Pisani;JIMD Rep,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative study on incorporation of three recombinant human α-galactosidase A drugs (agalsidases) into cultured fibroblasts and organs/tissues of Fabry mice;Molecular Genetics and Metabolism Reports;2024-09

2. Was ist gesichert in der Therapie von Morbus Fabry?;Die Innere Medizin;2024-08-06

3. Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis;Journal of Inherited Metabolic Disease;2024-07-04

4. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease;Frontiers in Genetics;2024-04-12

5. Interpretation of GFR slope in untreated and treated adult Fabry patients;Nephrology Dialysis Transplantation;2023-07-13